Kornimate/medical-research-clean huggingface dataset:
the effect of exercise on neurorecovery following mild traumatic brain injury

Conditions: Brain Concussion

Summary: the study is a "proof-of-principle" project to examine the safety and feasibility of implementing a 1-week aerobic exercise program in the post-acute phase after mild traumatic brain injury (mtbi). the study will define the extent to which the exercise program improves recovery from mtbi in terms of relevant functional outcomes (cognition, mood, and physical status) and biomarkers (peripheral brain-derived neurotrophic factor \[bdnf\] concentration).

this is a "proof-of-principle" project for human subjects to examine the safety and feasibility of implementing a 1-week aerobic exercise program in the post-acute phase after mild traumatic brain injury (mtbi). this study will define the extent to which the exercise program improves recovery from mtbi in terms of relevant functional outcomes (cognition, mood, and physical status) and biomarkers (peripheral brain-derived neurotrophic factor \[bdnf\] concentration). this project will also lay the foundation for understanding the relationship between exercise and bdnf in the area of mtbi neurorecovery, thereby allowing future studies to develop best-practice methods for implementing exercise interventions as a treatment option for brain injuries.

Eligibility criteria:
mild traumatic brain injury (mtbi) group: inclusion criteria: * meet criteria for mtbi as set forth by the american congress of rehabilitation medicine * mtbi was sustained 14-25 days before beginning the exercise intervention exclusion criteria: * comorbid orthopaedic injury that inhibits movement * history of serious psychiatric disturbance with hospitalization, * prior history of neurologic disease, * current or past history of substance abuse disorder, * diabetes * previous history of moderate or severe head injury, * neurological disorder unrelated to tbi (e.g., seizure disorder) * physician recommendations against exercise * non-english speakers non-injured group: inclusion criteria: - gainesville, florida community member exclusion criteria: * history of mtbi or other brain injury in the past year * comorbid orthopaedic injury that inhibits movement * history of serious psychiatric disturbance with hospitalization, * prior history of neurologic disease, * current or past history of substance abuse disorder, * diabetes * previous history of moderate or severe head injury, * neurological disorder unrelated to tbi (e.g., seizure disorder) * physician recommendations against exercise * non-english speakers

Keywords: mild traumatic brain injury aerobic exercise brain-derived neurotrophic factor
post-stroke aphasia tms

Conditions: Aphasia; Stroke; Language

Summary: the investigator proposes to examine the effects of excitatory transcranial magnetic stimulation (tms) combined with semantic feature analysis (sfa) language therapy to improve word-finding abilities in stroke survivors with aphasia (swa).

in this project, the investigator will use functional neuroimaging and inhibitory tms to determine precise therapy-responsive targets for excitatory tms therapy with sfa. one group of stroke survivors will receive sfa + tms targeting the precision site, and another group will receive sfa + tms targeting a control site. the primary outcome will be changes in picture naming accuracy. we expect that excitatory tms targeting a precision site would result in larger improvements in naming accuracy than tms targeting a control site. results will provide the efficacy of precision tms in post-stroke aphasia.

Eligibility criteria:
inclusion criteria: * diagnosed with left hemisphere stroke * consent date \>= 1 month after stroke onset * fluent in english * 18 years of age or older exclusion criteria: * severe cognitive, auditory or visual impairments that would preclude cognitive and language testing * presence of major untreated or unstable psychiatric disease (e.g. schizophrenia, bipolar disease) * a chronic medical condition that is not treated or is unstable * the presence of cardiac stimulators or pacemakers or intracardiac lines, neurostimulators, medication infusion device, any other implants near the scalp (e.g., cochlear implants) or in the eye, metal in the body (e.g., splinters, fragments, clips) * pregnancy * history of skull fractures, or skin diseases * history of ongoing or unmanaged seizures * presence of factors that potentially decrease seizure thresholds: on pro-convulsant medications, untreated sleep deprivation or insomnia, ongoing alcoholism or illegal drug abuse (e.g., cocaine or mdma users) * history of dyslexia or other developmental learning disabilities

Keywords: aphasia stroke language tms
bbo-11818 in adult subjects with kras mutant cancer

Conditions: Non-Small Cell Lung Cancer; NSCLC; PDAC - Pancreatic Ductal Adenocarcinoma; CRC (Colorectal Cancer); Metastatic Non-Small Lung Cell Cancer; Metastatic Colorectal Cancer (CRC); KRAS G12A; KRAS G12C; KRAS G12D; KRAS G12S; KRAS G12V; Metastatic Pancreatic Ductal Adenocarcinoma; Advanced Lung Carcinoma; Solid Tumor, Adult

Summary: a first in human study to evaluate the safety and preliminary antitumor activity of bbo-11818, a pan-kras inhibitor, in subjects with locally advanced unresectable or metastatic kras mutant solid tumors.

this is an open-label, multi-center, phase 1 study designed to evaluate the safety, tolerability, pharmacokinetics, and efficacy of bbo-11818, a pan-kras inhibitor, alone and in combination with pembrolizumab, pembrolizumab +/- cis/carboplatin + pemetrexed, or cetuximab in subjects with locally advanced unresectable or metastatic kras mutant solid tumors. the study includes dose escalation phase and dose expansion phase.

Eligibility criteria:
inclusion criteria: * histologically documented locally advanced and unresectable or metastatic nsclc, pdac, crc, or other solid tumor with kras g12a, g12c, g12d, g12s, or g12v mutation, or kras-amplification * measurable disease by recist v1.1 * eastern cooperative oncology group (ecog) performance status (ps) 0-1 exclusion criteria: * malignancy within the last 2 years as specified in the protocol * untreated brain metastases * known hypersensitivity to bbo-11818 or its excipients other inclusion/exclusion criteria are specified in the protocol.

Keywords: bbot bridgebio oncology therapeutics phase1 phase 1a/1b nsclc crc pdac metastatic cancer advanced cancer pembrolizumab cetuximab platinum chemotherapy pemetrexed konquer konquer-101
epidemiology and treatment strategy of open respiratory phenotype in critically ill patients

Conditions: Mechanical Ventilation Pressure High; Critical Illness

Summary: monitoring airway pressure is essential for patients with mechanical ventilation. however, static airway pressure does not reflect alveolar pressure at all. airway pressure is supposed to completely interrupt the communication between proximal airway opening and the distal alveolar and/or small airway structures. in this condition, some alveoli may still be inflated but do not communicate with proximal airways and auto-peep will give a biased estimated of mean alveolar pressure. to be note, distinguishing the airway closure and alveolar collapse can be challenging at times. the quasi-static pv curve is a useful bedside tool to set mechanical ventilation, which may help us to identify the airway closure and alveolar collapse. meanwhile, the quasi-static pv curve can only reflects a global behaviour of the lung, while eit may be a useful tool to assess the regional information on airway closure and alveolar collapse.


Eligibility criteria:
inclusion criteria: * adult patients undergoing controlled mechanical ventilation * the duration of endotracheal intubation \< 48 hrs exclusion criteria: * severe hemodynamic instability * severe chronic lung disease requiring long-term home oxygen therapy * patients without analgesic sedation * decline to participate in the study * refusal to sign informed consent

Keywords: mechanical ventilation airway closure alveolar collapse
dobutamine versus placebo for low superior vena cava flow in newborns

Conditions: Hemodynamic Instability

Summary: low systemic flow as measured by doppler-echocardiography has been associated with poor neurological outcome. yet, it has not been systematically evaluated whether the treatment of this hemodynamic condition is beneficial or not. this study aims to evaluate if treating low systemic flow in preterm infants with dobutamine has any effect on the cerebral circulation and in newborn prognosis.

while rates of survival for very preterm infants are increasing, a significant number of these patients suffer from neurodevelopmental disabilities. the pathophysiology of brain injury in the preterm infant is unclear, although haemodynamic disturbances during the period of transitional circulation after birth leading to ischemia-reperfusion events seem to play an important role. up to one third of infants born under 30 weeks of gestation develop low systemic flow as measured by doppler-echocardiography (low superior vena cava flow, svcf); this finding has been associated with poor neurological outcome. yet, it has not been systematically evaluated whether the treatment of this hemodynamic condition is beneficial or not. this study aims to evaluate if treating low systemic flow in preterm infants with dobutamina, db, (inotrope-sympathicomimetic drug) has any effect on the cerebral circulation; specific interest of our research would be to target db dose for individual patient´s response. secondly, by means of two non-invasive technologies (cerebral and cardiac ultrasonography-doppler and near infrared spectroscopy, nirs), the investigators search to characterise eventual differences in brain perfusion patterns during the adaptation to the transitional circulation that might be associated with the development of brain injury in the most vulnerable population.

Eligibility criteria:
inclusion criteria * newborn infants born at ≤ 28 weeks of gestational age. * newborn infants born at \> 28 weeks of gestational age and ≤ 30 weeks of gestational age with moderate-severe respiratory distress syndrome, defined as the necessity of respiratory support with a mean pressure ≥ 4 cm h2o or fio2 ≥ 0.3 * admission at the nicu in the first 6 hours of life * inotrope treatment absent * inform consent signed exclusion criteria * early systemic hypotension, defined as a mean arterial pressure (map) lower than the gestational age, during at least 60 minutes and maintained after volume infusion * major congenital malformation * informed consent declined

Keywords: low superior vena cava flow functional echocardiography
comparison of left bundle branch area versus right ventricular septal pacing in patients with high-degree conduction disease after transcatheter aortic valve replacement (left bundle brave)

Conditions: Complete Heart Block; High Degree Second Degree Atrioventricular Block; Pacemaker-Induced Cardiomyopathy; Aortic Valve Stenosis

Summary: the purpose of the study is to investigate the superiority of chronic left bundle branch area pacing compared to traditional right ventricular (rv) septal pacing in patients with high-grade conduction disease after transcatheter aortic valve replacement (tavr). in this investigator initiated, multicenter, prospective, double-blinded, crossover study, chronic left bundle branch area pacing will be compared to chronic right ventricular septal pacing using echocardiographic measures of left ventricular systolic function in patients with a high cumulative ventricular pacing burden after tavr.


Eligibility criteria:
inclusion criteria: * subject has at least one of these conduction disturbances: 1. symptomatic (or hemodynamically significant) bradycardia or symptomatic persistent atrioventricular block including first-degree and mobitz i (wenckebach) or mobitz type ii atrioventricular bock 2. high-grade atrioventricular block 3. third-degree atrioventricular block * subject has undergone tavr (any valve system) in the last four weeks * subject is receiving a first-time pacemaker implant * subject's most recent documented ejection fraction (by any method) within the past 90 days prior to study enrollment is \> 50% (≥45% if visually estimated at the time of enrollment) * subject is a male or female at least 18 years old at the time of consent * subject is able to receive a left sided pectoral implant exclusion criteria: * subject has ever had a previous or has an existing implantable pulse generator (ipg), implantable cardiac defibrillator (icd) or biventricular (biv) implant * subject has more than mild para-valvular regurgitation following tavr implantation. * subject has lvef \< 45% if visually estimated at the time of enrollment * subject is indicated for a biventricular pacing device (crt-p or crt-d). * subject is enrolled in a concurrent study that may confound the results of this study * subject has a mechanical heart valve * subject is pregnant, or of childbearing potential and not on a reliable form of birth control * subject status post heart transplant * subject life expectancy less than 2 years
arthralgia during anastrozole therapy for breast cancer

Conditions: Early Breast Cancer

Summary: the purpose of this study is to describe the joint symptoms and structural joint changes under anastrozole as adjuvant treatment in postmenopausal women with early breast cancer.


Eligibility criteria:
inclusion criteria: * post menopausal woman with a breast cancer and scheduled for an adjuvant treatment with anastrozole * who performance status 0, 1 or 2 * provision of written informed consent exclusion criteria: * recurrence of breast cancer, inflammatory rheumatism * treatment by chondromodulator, oral glucocorticoid, aromatase inhibitor, anti estrogen, herceptin * diabetes treated by insulin * severe renal or hepatic disease * known hypersensitivity to anastrozole

Keywords: breast cancer treatment joint disorders
the effect of rosuvastatin on aortic stiffness in hemodialysis patients in the aurora study

Conditions: Hypercholesterolemia

Summary: to investigate the effect of rosuvastatin compared to placebo on the aortic stiffness in hemodialysis patients as measured by pulse wave velocity (at 3, 6 and 12 months)


Eligibility criteria:
inclusion criteria: * signed informed consent, between 50 and 80 years of age, end stage renal failure patients receiving hemodialysis exclusion criteria: * received statins within past 6 months, a clear indication for use of lipid altering drug, contra indication for lipid altering drug, history of statin induced myopathy items in very

Keywords: high blood cholesterol levels
pa behavior and hrqol in parkinson's disease patients patients: role of social cognitive variables

Conditions: Parkinson Disease; Idiopathic Parkinson Disease; Idiopathic Parkinson's Disease; Parkinson Disease, Idiopathic; Parkinson's Disease; Parkinson's Disease, Idiopathic

Summary: the primary aim of the study will be to examine social cognitive theory (sct) correlates, of physical activity (pa) participation and health-related quality of life (hrqol) in parkinson's disease participants.

the body of evidence in the physical therapy and rehabilitation literature supports that physical activity is associated with improvements in quality of life for parkinson's disease (pd) patients. however, few studies have examined the underlying variables that may account for this relationship in pd patients. researchers have examined stages of readiness to exercise in pd patients and barriers to exercise and found a strong association between self-efficacy and exercise in pd patients, rather than disability . researchers suggest that social cognitive theory (sct) constructs are important correlates of physical activity for pd patients and should be targeted in interventions. a more comprehensive study of sct correlates - self-efficacy (se), outcome expectations (oe), and self-regulation (sr) should provide a better understanding of the factors that contribute to physical activity participation and the physical activity / health-related quality of life relationship in pd patients.

Eligibility criteria:
inclusion criteria: 1. english speaking 2. parkinson's disease diagnosed by a neurologist exclusion criteria: 1. atypical parkinson's 2. supranuclear palsy 3. deep brain stimulation (dbs) or other brain surgery 4. not living independently (living in assisted-living or skilled-nursing facility) 5. spouse or caregiver responding instead of pd participant

Keywords: social cognitive theory physical activity quality of life parkinsons
spectroscopy from duodenum

Conditions: Pancreatic Adenocarcinoma

Summary: purpose of this study is to understand the clinical feasibility of duodenal spectroscopy to adenocarcinoma patients.

pancreatic cancer (pc) is the most lethal of all major cancers with a five year survival rate of 5 %. while stage i and ii tumors leads to an improvement in survival, almost all pcs are currently diagnosed at more advanced non-resectable stages since minimally invasive technique which is capable of screening early-stage pc does not exist. serum ca19-9 is not recommended as a screening technique because of its low sensitivity and specificity. imaging modalities such as mri, ct, eus and ercp are more accurate but are not appropriate screening tools due to their high cost, discomfort and complications. therefore, there is a strong demand for a screening tool with high sensitivity and specificity which is highly acceptable for the patient. the investigators would like to look at the spectroscopy technique for pancreatic cancer diagnosis via an upper endoscopy. a definite diagnosis of the patient is made with histology, cytology or imaging diagnosis. therefore this study can be positioned as a feasibility study.

Eligibility criteria:
inclusion criteria: * common inclusion criterion * age is 18 years or older. * informed consent was obtained. * inclusion criterion for normal cohort * an upper gi endoscopy is scheduled to check upper abdominal symptoms. * no findings of pancreatic disorder as documented by ct or mri or eus * inclusion criterion for pc suspicious cohort \* a eus or ercp is scheduled to suspected pancreatic disorder. exclusion criteria: * common exclusion criterion * severe cardiac disease * severe respiratory disease * bleeding disorders * pregnancy

Keywords: pancreatic adenocarcinoma
arv concentrations in hair

Conditions: HIV

Summary: hair samples from subjects on antiretroviral therapy, both hiv- and hiv+ patients with hiv rna \ 6 months will be analyzed to investigate the influence of race, hair color and hair treatment on arv response.

a small thatch of hair (approximately 20 strands) will be collected from 85 participants who are currently taking antiretrovirals (arvs). hair collection will be evenly distributed into color cohorts: black, brown, blonde and grey. participants will need to be \>80% adherent to their medication and have had an undetectable hiv rna vl within the previous 6 months. in the lab, samples will be used to develop ir-maldesi msi hair protocols for high sensitivity and accuracy to quantify arvs in 5 therapeutic drug classes (integrase inhibitors, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, entry inhibitors, protease inhibitors).

Eligibility criteria:
inclusion criteria: * hiv negative or hiv positive individuals, aged 18 years or older, who have been taking their arv medication for at least 3 months and are adherent based on blood plasma hiv rna of \<50 copies/ml or hiv negative status. exclusion criteria: * subjects non-adherent to anti-retroviral regimen * subjects not willing or able to provide head hair sample

Keywords: hair
comparison of colonoscopy and sigmoidoscopy in terms of pain, acceptance and procedure time

Conditions: Pain

Summary: according to experience in a self-payed health check-up center,unsedated total colonoscopy is not inferior or may be better than unsedated sigmoidoscopy in terms of pain and patients' acceptance. hypothesis: unsedated total colonoscopy is not inferior to unsedated sigmoidoscopy in terms of pain and patients' acceptance.

according to american cancer society guideline, screening total colonoscopy every 10 years or sigmoidoscopy every 5 years is recommended for average risk people above 50 years old. however,study in taiwanese population demonstrated that 37.8% of colorectal lesions were beyond reach of sigmoidoscope, and in cases with lesions with advanced pathology, 66.7% did not have distal colorectal lesion. however, many people think colonoscopy is more painful and choose sigmoidoscopy for screening. however, according to experience in a self-payed health check-up center,unsedated total colonoscopy is not inferior or may be better than unsedated sigmoidoscopy in terms of pain and patients' acceptance.

Eligibility criteria:
inclusion criteria: * subjects who undergo self-payed unsedated colonoscopy or sigmoidoscopy for colon cancer screening. exclusion criteria: * difficulty in assessing pain during the procedure and acceptance for the procedure

Keywords: colonoscopy sigmoidoscopy colon cancer screening pain screening
comparison of gabapentin with doxepin in the management of uremic pruritus

Conditions: Uremic Pruritus

Summary: this is a single blind randomized trial to compare efficacy and side effects of gabapentin with doxepin. hemodialysis patients with uremic pruritus at one dialysis center of saint george hospital university medical centre were included in this study. patients were divided into 2 groups to receive either 10 mg doxepin daily or gabapentin at a dose of 100mg after each hemodialysis session (increased as tolerated) for 4 weeks, after which patients were treated reversley. pruritus severity and its effect on quality of life will be assessed by using visual analog scale (vas), 5-d pruritus scale and dermatology life quality index (dlqi). include patients will have to fill these forms at baseline and at end of week1, week2 and week4

pruritus is one of the frustrating skin manifestations of advanced renal failure. many options have been used for the management of uremic pruritus (up) such as pregabalin, gabapentin, doxepine and desloratidine. gabapentin, a gabaergic drug, has been found to be effective in the treatment of uremic pruritus. doxepin, a potent antihistamine drug, is used orally or topically in many pruritic conditions such as up, idiopathic pruritus, atopic dermatitis, neurogenic, or psychogenic pruritus and, in the management of the up in hemodialysis patients. no comparative head to head study between gabapentin and doxepine has been conducted to date. the aim of this study was to compare gabapentin and doxepin in treatment of uremic pruritus in hemodialysis patients.

Eligibility criteria:
inclusion criteria: * prevalent patients undergoing hd with up for at least three months * any medications with antipruritic effects to be discontinued one week before the study * hemodialysis performed for 3-4 h thrice weekly via a low flux polysulphonedialyser \[1.3-1.6 m2 surface areas\] using bicarbonate and/or acetate dialysis fluid * well controlled calcium, phosphorus and ipth levels exclusion criteria: * patients labeled high risk of fall (having a score more than 16/20 using part 1 from falls risk assessment tool (frat) * patients taking drugs that interact with doxepin or gabapentin * patients with hepatic failure * patients with hyperthyroidism * patients with narrow angle glaucoma * patients with heart block or decompensated heart failure or hypotension (defined as systolic blood pressure less than 90 mmhg) or myocardial infarction in the past three months * history of allergy to gabapentin or doxepin * uncontrolled psychiatric diseases * pregnant patients * patients with psoriasis, atopic dermatitis or any other condition that can justify the pruritus